Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs) EQUITY
$58.76
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | BMY Avg Daily Volume: 9,537,200
Last Update: 08/29/16 - 4:01 PM EDT
Volume: 0
YTD Performance: -14.58%
Open: $0.00
Previous Close: $58.76
52 Week Range: $56.32 - $77.12
Oustanding Shares: 1,670,858,535
Market Cap: 98,196,356,102
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 7 7 7
Moderate Buy 0 1 1 1
Hold 10 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.65 2.32 2.32 2.32
Latest Dividend: 0.38
Latest Dividend Yield: 2.59%
Dividend Ex-Date: 10/05/16
Price Earnings Ratio: 21.06
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
21.06 63.20 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-17.60% -3.05% 40.61%
GROWTH 12 Mo 3 Yr CAGR
Revenue 4.30 -0.10 -0.02
Net Income -19.60 -0.30 -0.13
EPS -22.50 -0.20 -0.07
Earnings for BMY:
EBITDA 2.27B
Revenue 16.56B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $0.62 $0.57 $2.64 $3.08
Number of Analysts 7 6 12 12
High Estimate $0.68 $0.61 $2.69 $3.31
Low Estimate $0.53 $0.51 $2.49 $2.68
Prior Year $0.39 $0.38 $2.01 $2.64
Growth Rate (Year over Year) 59.71% 49.12% 31.26% 16.87%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Aug 22, 2016 | 12:27 PM EDT
Investors need to read the Real Money commentary regarding Bristol Myers to get a true read on the stock, said TheStreet's Jim Cramer.
By

Timothy Collins

 | Aug 19, 2016 | 12:42 PM EDT
I do think we could rebound back into the $61-$62 range.
By

Jim Cramer

 | Aug 17, 2016 | 8:09 AM EDT
Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.
By

Jim Cramer

 | Aug 11, 2016 | 7:38 AM EDT
Go ahead and sell Valeant on the news, if you want. But history has a different lesson.
By

Tim Melvin

 | Aug 9, 2016 | 2:00 PM EDT
There's a price to pay for low expectations.
By

Chris Laudani

 | Aug 9, 2016 | 10:00 AM EDT
BMY is unlikely to stay in the low $60s for long.
By

Jim Cramer and Jack Mohr

 | Aug 8, 2016 | 3:39 PM EDT
The failed trial is among the biggest single blows by a major pharma player.
By

Guy Ortmann

 | Aug 8, 2016 | 2:30 PM EDT
Energy, financial and technology stocks dominate names showing potential for higher prices.
By

James Passeri

 | Aug 8, 2016 | 12:43 PM EDT
Rising crude prices help buoy a host of oil companies Monday.
By

Jim Cramer

 | Aug 8, 2016 | 11:56 AM EDT
Jim Cramer says the markets don't understand Bristol-Myers Squibb and Allergan.
The Emini S&P 500 (ES) is grinding higher off of Friday's Fischer Low at 2157.50 into ...
Mylan (MYL) says the "generic" EpiPen will be identical to the current one at about half ...
There is a long term zone of support on the weekly chart of the PowerShares DB US Dollar B...
Market off to a decent start with all three major indices slightly up even as oil begins t...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.